Equity Overview
Price & Market Data
Price: $28.10
Daily Change: +$0.10 / 0.36%
Daily Range: $27.44 - $28.81
Market Cap: $1,825,360,768
Daily Volume: 143,778
Performance Metrics
1 Week: 5.64%
1 Month: 2.14%
3 Months: 17.23%
6 Months: 22.17%
1 Year: 70.30%
YTD: 1.26%
Company Details
Employees: 108
Sector: Health technology
Industry: Biotechnology
Country:
Details
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist for the treatment of attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), as well as in Phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.